C5 and atypical hemolytic-uremic syndrome: Therapeutic inhibition of complement, especially at the level of C5 using agents such as eculizumab, has been successfully used to treat conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [60].